

**Förenade kungariket-Bristol: Patologiska tjänster**  
**OJ S 21/2020 30/01/2020**  
**Meddelande om frivillig förhandsinsyn**  
**Tjänster**

**Rättslig grund:**  
direktiv 2014/24/EU

## Avsnitt I: Upphandlande myndighet/enhet

---

### I.1. Namn och adresser

Officiellt namn: North Bristol NHS Trust  
Postadress: Southmead Road, Bristol  
Ort: Bristol  
Nuts-kod: UKK11 Bristol, City of  
Postnummer: BS10 5NB  
Land: Förenade kungariket  
Kontaktperson: Martin Strawson  
E-post: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)  
Telefon: +44 1173420815  
**Internetadress(er):**  
Allmän adress: <https://www.nbt.nhs.uk/>

### I.4. Typ av upphandlande myndighet

Annan typ: NHS trust

### I.5. Huvudsaklig verksamhet

Hälsa- och sjukvård

## Avsnitt II: Föremål

---

### II.1. Upphandlingens omfattning

#### II.1.1. Benämning på upphandlingen

Procurement of a Large Throughput DNA Sequencer  
Referensnummer: BWPCCL001501

#### II.1.2. Huvudsaklig CPV-kod

85111800 Patologiska tjänster

#### II.1.3. Typ av kontrakt

Tjänster

#### II.1.4. Kort beskrivning

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

#### **II.1.6. Information om delar**

Kontraktet är uppdelat i flera delar: nej

#### **II.1.7. Upphandlingens totala värde**

Värde exkl. moms: 779 625,00 GBP

### **II.2. Beskrivning**

#### **II.2.2. Ytterligare CPV-kod(er)**

85111000 Sjukhustjänster

#### **II.2.3. Plats för utförande**

Nuts-kod: UKK11 Bristol, City of

#### **II.2.4. Beskrivning av upphandlingen**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **II.2.5. Tilldelningskriterier**

Kvalitetskriterium - Namn: Quality / Viktning: 90

Pris - Viktning: 10

#### **II.2.11.**

## Information om optioner

Option: nej

### II.2.13. Information om EU-medel

Kontraktet är knutet till projekt och/eller program som finansieras med EU-medel: nej

### II.2.14. Kompletterande upplysningar

## Avsnitt IV: Förfarande

---

### IV.1. Beskrivning

#### IV.1.1. Typ av förfarande

Tilldelning av kontrakt utan att ett meddelande om upphandling först offentliggjorts i Europeiska unionens officiella tidning, i de fall som räknas upp nedan

- Kontraktet ligger utanför direktivets tillämpningsområde

Förklaring:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### IV.1.3. Information om ramavtal

#### IV.1.8. Information om avtalet om offentlig upphandling

Upphandlingen omfattas av avtalet om offentlig upphandling: nej

### IV.2. Administrativ information

## Avsnitt V: Tilldelning av kontrakt/koncessioner

---

### Benämning på upphandlingen:

Procurement of Large High Throughput DNA Sequencer

### V.2. Tilldelning av kontrakt/koncessioner

#### V.2.1. Datum för beslut om tilldelning av kontrakt

28/01/2020

#### V.2.2. Information om anbuden

Kontraktet har tilldelats en grupp av ekonomiska aktörer: nej

#### V.2.3. Entreprenörens/koncessionshavarens namn och adress

Officiellt namn: Illumina Cambridge Ltd

Postadress: Chesterford Research Park, Little Chesterford

Ort: Saffron Walden

Nuts-kod: UKI London

Postnummer: CB10 1XL

Land: Förenade kungariket

Uppdragstagaren/koncessionsinnehavaren kommer att vara ett litet eller medelstort företag: ja

#### V.2.4. Upplysningar om kontraktets/delens/koncessionens värde

Kontraktets/delens/koncessionens totala värde: 779 625,00 GBP

#### V.2.5. Information om underentreprenader

## Avsnitt VI: Kompletterande upplysningar

---

### VI.3. Kompletterande upplysningar

### VI.4. Överprövningsförfaranden

#### VI.4.1. Behörigt organ vid överprövning

Officiellt namn: Bristol and Weston Purchasing Consortium

Postadress: Level 3, Whitefriars, Lewins Mead

Ort: Bristol

Postnummer: BS1 2NT

Land: Förenade kungariket

E-post: [martin.strawson@UH Bristol.nhs.uk](mailto:martin.strawson@UH Bristol.nhs.uk)

#### VI.4.2. Behörigt organ vid medling

Officiellt namn: Bristol and Weston Purchasing Consortium

Postadress: Level 3, Whitefriars, Lewins Mead

Ort: Bristol

Postnummer: BS1 2NT

Land: Förenade kungariket

#### VI.4.4. Organ som kan lämna information om överprövning

Officiellt namn: Bristol and Weston Purchasing Consortium

Postadress: Level 3, Whitefriars, Lewins Mead

Ort: Bristol

Postnummer: BS1 2NT

Land: Förenade kungariket

**VI.5. Datum då meddelandet sänts**

28/01/2020